Back to search

Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).

J. R. Infante, G. S. Falchook, Donald P. Lawrence, J. S. Weber, Richard Kefford
DOI: 10.1200/jco.2011.29.18_suppl.cra8503
Journal of Clinical Oncology

Data up to Jan 2025

Published2011
Citations123
References0
Fields
MedicineBiologyInternal medicinePharmacologyGastroenterology

Total Citations Per Year

Abstract

References (0)

No references found

Cited By (0)

Loading...
Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2… (2011) – Journal of Clinical Oncology | Metascience Observatory Explorer